mk-4232
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2010 (NCT01315847)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 11-carbon
Oral
No
Parenteral
No
Topical
No
Also known as
- 2-(8-(3,5-difluorophenyl)-6,8-(6-11c)dimethyl-10-oxo-6,9-diazaspiro(4.5)decan-9-yl)-n-(2'-oxospiro(1,3-dihydroindene-2,3'-1h-pyrrolo(2,3-b)pyridine)-5-yl)acetamide
- 2-(8-(3,5-difluorophenyl)-6,8-dimethyl-10-oxo-6,9-diazaspiro(4.5)decan-9-yl)-n-(2'-oxospiro(1,3-dihydroindene-2,3'-1h-pyrrolo(2,3-b)pyridine)-5-yl)acetamide
- mk-4232
- mk-4232
- mk-4232
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01315847 | Phase 1 | Jan 1, 2010 | Merck |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 1 | 1 | 1 | 2010 |
1 organizations
Page 1 / 1